Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Impact of Oncotype DX Risk Categorization and Receipt of Chemotherapy on Survival Outcomes Among Patients with Small Node-Negative HR+ Breast Cancer.

The oncologist·2026
Same author

Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.

Breast cancer research : BCR·2026
Same author

Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

Molecular cancer therapeutics·2026
Same author

Perineural Spread and Base of Skull Involvement in Cutaneous Squamous Cell Carcinoma-A Critical Review from an Endemic Region.

Current oncology (Toronto, Ont.)·2026
Same author

QuTILs: Open-Source Image-Based Infiltrating Immune Cell Detection for Research Application.

Research square·2026
Same author

ASO Visual Abstract: Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age.

Annals of surgical oncology·2026

相关实验视频

Updated: Mar 27, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

在三阴性乳腺癌中对BET代体抑制剂的反应和耐药性

Shaokun Shu1,2, Charles Y Lin1,2, Housheng Hansen He1,2,3,4,5

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Nature
|January 7, 2016
PubMed
概括

三重阴性乳腺癌 (TNBC) 显示出BET代酶抑制剂的前景,提供了潜在的新疗法. 研究揭示了耐药性机制,建议结合策略以改善治疗结果.

更多相关视频

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.1K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.8K

相关实验视频

Last Updated: Mar 27, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.1K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.8K

科学领域:

  • 癌症学
  • 分子生物学
  • 遗传学

背景情况:

  • 三重阴性乳腺癌 (TNBC) 是一种缺乏向治疗的侵袭性亚型.
  • 在其他癌症中,BET胺抑制剂已显示出有效性,但在TNBC中仍未评估.
  • 这些抑制剂通过从染色质中取代BET蛋白来向瘤转录程序.

研究的目的:

  • 评估BET代酶抑制剂在TNBC中的疗效.
  • 研究TNBC中对BET抑制的获得性耐药性的机制.
  • 确定潜在的组合策略来克服抗药性.

主要方法:

  • 在体外和体内研究TNBC对BET抑制的敏感性.
  • 为获得抗性选择的配对细胞系的分析.
  • 蛋白质学研究以确定耐药细胞中的分子变化.
  • 评估BRD4依赖性和翻译后的修改.

主要成果:

  • 对于BET代体抑制,TNBC表现出优越的敏感性.
  • 获得的耐药性不涉及守门者突变,新驱动因素或药物激活.
  • 耐药细胞依赖于野生型BRD4以原体独立的方式.
  • 由于PP2A活性下降而导致的MED1关联和BRD4高酸化是耐药细胞的特征.

结论:

  • BET 代蛋白抑制是一种有前途的TNBC 治疗策略.
  • 了解涉及BRD4和PP2A的抵抗机制至关重要.
  • 基于机制的组合策略有可能克服TNBC的临床耐药性.